finally!! i think any drop will be made back up by the end of the day, based on recent trading patterns, last time we saw a drop of about 15p, which it quickly bounced back from.
RE: 'anecdotal' cancer cure
absolutely, im not the one saying it, JG did during the jefferies presentation....which seemed odd, hence why it is beyond me that he would say such a thing..(unless its politics) have a listen.. http://ir.gwpharm.com/events.cfm
RE: 'anecdotal' cancer cure
GW do have an interest in THC, Sativex has THC in it doesn't it?
GW Pharmaceuticals to Report Q4, Year-End 2014 Financial Results and Host Conference Call on 2 December, 2014 LONDON, Nov. 24, 2014 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will report on 2 December, 2014 its fourth quarter, year-end financial results for the period ending 30 September, 2014. GW will also host a conference call the same day at 8:00 a.m. EST/1:00 p.m. GMT. Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call. About GW Pharmaceuticals plc Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer. This Phase 3 program has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) and is intended to support the submission of a New Drug Application for Sativex in cancer pain with the FDA and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex® in the treatment of childhood epilepsy, which has received Fast Track Designation from the FDA for Dravet syndrome as well as Orphan Drug Designations from the FDA in both the treatment of Dravet syndrome and Lennox-Gastaut syndrome. GW's product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com. Enquiries: GW Pharmaceuticals plc(Today) +44 20 3727 1000 Justin Gover, Chief Executive Officer(Thereafter) + 44 1980 557000 Stephen Schultz, VP Investor Relations (U.S.)917 280 2424 / 401 500 6570 FTI Consulting (Media Enquiries) Ben Atwell / Simon Conway / John Dineen (UK)+ 44 20 3727 1000 Robert Stanislaro (U.S.)212 850 5657 Trout Group, LLC (U.S. investor relations) Todd James / Chad Rubin646 378 2900 Source: GW Pharmaceuticals plc
'anecdotal' cancer cure
quite few of these type of vids on the net, what i find interesting about this one is the 'backdoor' delivery method employed that reputedly reduced the psychoactive effects of the high strength THC, also she had no radiation therapy, worth a watch esp if you happen to be justin gover, how GWP can suggest that they have no interest in THC is beyond me*..all the evidence suggests it is highly theraputic, unlike politics, so who are we trying to help here, the patients or the politicians.... https://www.youtube.com/watch?v=-hUoyXKf81c&feature=youtu.be *JG made this comment during the jefferies presentation
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.